Welcome to our dedicated page for Inspire Medical news (Ticker: INSP), a resource for investors and traders seeking the latest updates and insights on Inspire Medical stock.
Inspire Medical Systems Inc. (NYSE: INSP) provides innovative neurostimulation solutions for obstructive sleep apnea (OSA) treatment. This news hub offers investors and healthcare professionals centralized access to official updates, including FDA milestones, clinical trial results, and strategic developments.
Track the company’s progress in advancing minimally invasive therapies through verified press releases, regulatory filings, and market expansion announcements. Key updates include earnings reports, partnership agreements, and advancements in OSA treatment technology.
Discover how Inspire Medical maintains compliance with global medical device standards while delivering clinically validated solutions. Content is organized chronologically for efficient research, with clear sourcing to ensure reliability.
Bookmark this page for real-time updates on INSP’s neurostimulation innovations and their impact on sleep medicine. For comprehensive analysis, combine these primary sources with third-party market commentary available across Stock Titan.
Inspire Medical Systems (NYSE: INSP) announced preliminary Q4 2024 revenue of $239.5-239.7 million, up 25% year-over-year, and full-year 2024 revenue of $802.6-802.8 million, representing 28% growth. The company provided initial 2025 revenue guidance of $940-955 million, projecting 17-19% growth.
Key operational highlights include activating 72 new U.S. centers in Q4, reaching 1,435 total implanting centers, and creating 12 new sales territories, totaling 335. The company successfully launched the Inspire V neurostimulator with over 40 implants in Singapore and the U.S.
Organizational changes include appointing Jason Kelly as Chief Manufacturing and Quality Officer, Carlton Weatherby expanding to Chief Strategy and Growth Officer, Randy Ban transitioning to EVP of Patient Access and Therapy Development, and new roles for Ivan Lubogo and Joe Sander in strategic and U.S. sales leadership.
Inspire Medical Systems (NYSE: INSP) has announced it will release its fourth quarter and fiscal 2024 financial results after market close on Monday, February 10, 2025. The company's management will host a conference call at 5:00 p.m. Eastern Time to discuss financial results and recent business developments.
The earnings call will be accessible through two options: a webcast via the company's Investor Relations page for those planning to listen only, and a separate registration link for participants who wish to ask questions. Participants planning to ask questions are advised to register at least 10 minutes before the call. A replay will be available on the Investor Relations website approximately two hours after the event and will remain archived for two weeks.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company's management team is scheduled to present on Monday, January 13, 2025, at 11:15 a.m. Eastern Time.
The presentation will be available through a live webcast, with replay access remaining available for two weeks afterward in the Event Archive section of Inspire's Investor website at investors.inspiresleep.com.
Presidio Medical has appointed Richard J. Buchholz to its Board of Directors. Buchholz currently serves as Chief Financial Officer of Inspire Medical Systems (NYSE: INSP), where he has been instrumental in driving strategic financial and operational growth.
With extensive experience in healthcare finance, including previous CFO roles at superDimension and Vascular Solutions, Buchholz brings valuable expertise to Presidio Medical, a clinical stage company developing neuromodulation platforms. The appointment aligns with Presidio's strategy to strengthen its leadership team as it advances through key growth and development stages.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Piper Sandler 36th Annual Healthcare Conference. The presentation is scheduled for Tuesday, December 3, 2024, at 12:00 p.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replays available for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 20, 2024, at 7:30 a.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replays available for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems has initiated a $75 million accelerated share repurchase (ASR) program with Goldman Sachs, as part of its previously announced $150 million share repurchase authorization. The ASR transaction is scheduled to conclude in Q1 2025. The company's decision reflects confidence in its long-term growth potential, supported by strong revenue and earnings growth. The broader repurchase program, set to expire on August 5, 2026, allows for flexible implementation through various transaction methods and can be modified or discontinued at the company's discretion.
Inspire Medical Systems (NYSE: INSP), a medical technology company specializing in minimally invasive solutions for obstructive sleep apnea, has announced its participation in the Jefferies London Healthcare Conference. The presentation is scheduled for Wednesday, November 20, 2024, at 11:00 a.m. Eastern Time. Interested parties can access the presentation through a live webcast, with replay availability for two weeks afterward on the company's investor website at investors.inspiresleep.com.
Inspire Medical Systems reported strong Q3 2024 financial results with revenue of $203.2 million, up 33% year-over-year. The company achieved a gross margin of 84.1% and generated operating income of $14.3 million. Earnings per share reached $0.60, compared to a loss of $0.29 in the prior year period.
The company activated 66 new U.S. centers and created 13 new sales territories, bringing totals to 1,371 centers and 323 territories. Based on strong performance, Inspire raised its full-year 2024 revenue guidance to $793-798 million and increased EPS guidance to $1.20-1.40.
Inspire Medical Systems (NYSE: INSP) announced its upcoming participation in the UBS Global Healthcare Conference. The medical technology company, which specializes in minimally invasive solutions for obstructive sleep apnea, will present on Wednesday, November 13, 2024, at 11:00 a.m. Eastern Time.
The presentation will be available through a live webcast, with replay access remaining available for two weeks afterward in the Event Archive section of Inspire's Investor website.
FAQ
What is the current stock price of Inspire Medical (INSP)?
What is the market cap of Inspire Medical (INSP)?
